NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $33.46 +2.51 (+8.11%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$33.30 -0.16 (-0.46%) As of 07/21/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cue Biopharma Stock (NASDAQ:CUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$29.93▼$35.0050-Day Range$20.03▼$36.7852-Week Range$4.97▼$45.50Volume110,142 shsAverage Volume126,056 shsMarket Capitalization$140.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation. Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies. Its most advanced candidate, CUE-101, is an HLA‐peptide‐cytokine fusion designed to stimulate T cells specific to HPV16‐positive cancers. Additional programs—such as CUE-102 and CUE-301—seek to address solid tumors and viral infections by harnessing the same platform technology to selectively expand disease-relevant T cell populations. The company’s research and manufacturing activities are conducted primarily in the United States, with collaborations and partnerships aimed at accelerating clinical development. Under the leadership of President and CEO Darren Cline, Cue Biopharma has completed its initial public offering in 2021 and continues to build its research capabilities through strategic alliances with academic institutions and contract development organizations. The management team combines expertise in immunology, protein engineering and clinical development, positioning the company to advance its pipeline toward key clinical milestones. With its unique CRT platform, Cue Biopharma seeks to offer differentiated, antigen‐specific immunotherapies that may overcome limitations of current cytokine and cell‐based treatments.AI Generated. May Contain Errors. Read More Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCUE MarketRank™: Cue Biopharma scored higher than 7% of companies evaluated by MarketBeat, and ranked 1659th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCue Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCue Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -5.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.31% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently increased by 8.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. News and Social Media2.7 / 5News SentimentN/A News SentimentCue Biopharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 3 articles on an average week.Search Interest5 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows2 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders14.56% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUE Stock News HeadlinesCue Biopharma names Dominic Borie as CMO and head of R&DJuly 13, 2026 | msn.comCue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & DevelopmentJuly 13, 2026 | globenewswire.comNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, produces zero carbon, and needs no fuel, no batteries, or sunlight. A crew near the Grand Canyon drilled three miles underground in just 16 days. Google signed a 15-year contract, Bill Gates invested $100 million, and the Pentagon called it priority one. On August 18th, Washington grants this energy source a competitive advantage through 2033. | Behind the Markets (Ad)Cue Biopharma Shares Rise on $50 Million Private Placement PricingJuly 11, 2026 | marketwatch.comCue: The Market Is Paying $86M For A Drug It Doesn't OwnJuly 11, 2026 | seekingalpha.comCue Biopharma to raise $50M in oversubscribed private placementJuly 10, 2026 | msn.comCue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset ManagementJuly 9, 2026 | quiverquant.comQCue Biopharma Announces $50.0 Million Private PlacementJuly 9, 2026 | globenewswire.comSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $274.86 at the start of the year. Since then, CUE stock has decreased by 87.8% and is now trading at $33.46. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($3.30) by $2.22. The company earned $5.69 million during the quarter, compared to the consensus estimate of $2.50 million. Cue Biopharma had a negative trailing twelve-month return on equity of 98.30% and a negative net margin of 59.65%. When did Cue Biopharma's stock split? Shares of Cue Biopharma reverse split on the morning of Thursday, April 23rd 2026.The 1-30 reverse split was announced on Wednesday, April 22nd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 22nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cue Biopharma IPO? Cue Biopharma (CUE) raised $62 million in an initial public offering on Tuesday, January 2nd 2018. The company issued 8,820,710 shares at $6.00-$8.00 per share. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Company Calendar Last Earnings5/14/2026Today7/21/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CUE's financial health is in the Green zone, according to TradeSmith. CUE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees60Year Founded2015Profitability EPS (Trailing Twelve Months)($5.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.60 million Net Margins-59.65% Pretax Margin-58.12% Return on Equity-98.30% Return on Assets-53.69% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.57 Sales & Book Value Annual Sales$27.47 million Price / Sales5.12 Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book3.32Miscellaneous Outstanding Shares4,200,000Free Float3,588,000Market Cap$140.53 million OptionableOptionable Beta2.45 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CUE) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe SpaceX IPO Wasn't For YouJust one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...Freedom Financial | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...Behind the Markets | SponsoredForget Tariffs - “Digital Goldmines” are the biggest story in America todayWhile investors focus on Nvidia, Tesla, and Meta, one overlooked company may be quietly profiting from AI infr...Eagle Publishing | SponsoredForget SpaceX… this is the REAL #1 IPO of 2026While SpaceX and OpenAI dominate IPO headlines, one private company is reportedly seeing the fastest revenue g...The Oxford Club | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
